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Abstract
Endometrial receptivity is mediated by adhesion molecules at the endometrium-trophoblast interface where osteopontin (OPN) and
CD44 form a protein complex that plays an important role in embryo recognition. Here, we undertook a prospective study investi-
gating the expression and regulation of OPN and CD44 in 50 fertile and 31 infertile ovulatory polycystic ovarian syndrome (PCOS)
patients in the proliferative and secretory phases of the natural menstrual cycle and in 12 infertile anovulatory PCOS patients.
Endometrial biopsies and blood samples were evaluated for expression of OPN and CD44 using RT-PCR, immunohistochemistry
and ELISA analysis to determine circulating levels of OPN, CD44, TNF-α, IFN-γ and OPN and CD44 levels in biopsy media. Our
findings highlighted an increased level of circulating OPN and CD44 in serum from infertile patients that inversely correlated with
expression levels in endometrial tissue and positively correlated with levels secreted into biopsy media. OPN and CD44 levels
positively correlated to each other in serum and media from fertile and PCOS patients, as well as to circulating TNF-α and IFN-γ.
In vitro analysis revealed that hormone treatment induced recruitment of ERα to the OPN and CD44 promoters with a concomitant
increase in the expression of these genes. In infertile patients, inflammatory cytokines led to recruitment of NF-κBand STAT1 proteins
to the OPN and CD44 promoters, resulting in their overexpression. These observations suggest that the endometrial epithelial OPN-
CD44 adhesion complex is deficient in ovulatory PCOS patients and displays an altered stoichiometry in anovulatory patients, which
in both cases may perturb apposition. This, together with elevated circulating and local secreted levels of these proteins, may hinder
endometrium-trophoblast interactions by saturating OPN and CD44 receptors on the surface of the blastocyst, thereby contributing to
the infertility associated with ovulating PCOS patients.
Key messages
• Endometrial epithelial OPN-CD44 adhesion complex levels are deficient in ovulatory PCOS patients contributing to the
endometrial infertility associated with ovulating PCOS patients.
• Circulating levels of OPN, CD44 and inflammatory cytokines TNF-α and IFN-γ are altered in infertile PCOS patients.
• Increased levels of both OPN and CD44 in biopsy media and serum inversely correlate with endometrial expression of these
markers in endometrial tissue.
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• In infertile PCOS patients, high levels of oestrogens and inflammatory cytokines stimulate the recruitment of transcription
factors to the OPN and CD44 promoters to enhance gene transcription.
• Our study identifies a novel crosstalk between the CD44-OPN adhesion complex, ERα, STAT1 and NF-κB pathways
modulating endometrial receptivity.
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Introduction
Endometrial receptivity depends on synchronous biochemi-
cal, structural and molecular events for successful embryo
implantation to occur during the window of implantation at
day 20 to 24 in the menstrual cycle. This is characterised by
optimal hormone levels, cytokine signalling and the presence
of luminal endometrial adhesion proteins, including osteopon-
tin (OPN) and CD44, to support the embryo attachment [1, 2].
Infertility conditions, including polycystic ovary syndrome
(PCOS), are associated with defective endometrial expression
of adhesion proteins [3]. In the fertile endometrium, expres-
sion of the oestrogen and progesterone nuclear hormone re-
ceptors, ERα and PR, is elevated during the proliferative
phase of the menstrual cycle, and then reduced with the rise
of progesterone after ovulation. However, in infertile PCOS
patients, expression of ERα and PR is elevated, leading to
altered expression of ERα- and PR-regulated proteins in-
volved in implantation [4].
CD44 is a transmembrane glycoprotein expressed during
the window of implantation [5] and has been implicated in the
migration and adhesion of endometrial cells [6]. The phospho-
glycoprotein, OPN, is also expressed during the window of
implantation acting as a bridging molecule between the endo-
metrial luminal surface and the trophoblast through interac-
tions with αvβ3 integrin and CD44 [5]. In the normal secre-
tory phase, endometrium CD44 expression is increased [7],
mirroring the expression of OPN, thus supporting a role for
CD44 in facilitating attachment of the blastocyst [8].
Variation of OPN and CD44 expression during the men-
strual cycle [9, 10] and the presence of regulatory elements for
ERα in the promoter regions of both OPN and CD44 suggest
that their expression is regulated by oestrogen, as well as pro-
gesterone acting through PR isoform B (PRB), at least for
OPN [11]. In the normal endometrium, oestrogen also
upregulates the expression of a number of inflammatory cyto-
kines including TNF-α, and IFN-γ, each of which has been
implicated in endometrium receptivity, with increased expres-
sion at the time of implantation [12, 13]. TNF-α, a potent pro-
inflammatory cytokine, is involved in the cyclic endometrial
regeneration [14]. IFN-γ induction also plays a key role in
implantation, particularly in the vascular remodelling process
through activation of the STAT1 pathway [15, 16]. In partic-
ular, alterations of the endometrial cytokine pattern have been
shown to influence the implantation process, with direct cor-
relation between recurrent miscarriage and high levels of
IFN-γ, and TNF-α reported [17]. Several studies have pro-
posed that pro-inflammatory molecules play a role in the com-
plex inflammatory cascade that is associated with PCOS [18].
For instance, elevated levels of TNF-α, TNFR2 receptors and
nuclear p65 have been reported in secretory endometrial tissue
of PCOS women, suggesting a sustained pro-inflammatory
uterine environment through enhanced activation of p65-
NF-κB pathway in these patients [19].
Therefore, this study aims to evaluate the endometrial ex-
pression and circulating levels of CD44 and OPN proteins in
infertile patients diagnosed with PCOS. The effects of steroid
hormones and pro-inflammatory cytokines on CD44 and OPN
gene and protein expressions were also assessed using in vitro
models. We hypothesised that changes in the ratios of endo-
metrial versus serum levels of these two molecules in PCOS
patients could lead to alterations in the stoichiometry of the
OPN-CD44 adhesion complex at the endometrial surface, thus
promoting the saturation of OPN and CD44 receptors on the
surface of the blastocyst by secreted molecules. Together,
such changes could prevent endometrium-trophoblast interac-
tions contributing to endometrial infertility in PCOS patients.
Materials and methods
Patients
The control group consisted of women with proven fertility,
all parous (parity 1–5) and with confirmed ovulation in the
tested cycles. These patients were recruited from general gy-
naecology clinics, having presented for sterilisation with no
confirmed diagnosis of PCOS. The infertile group consisted of
women diagnosed with PCOS. Endometrial biopsies were ob-
tained from women in a natural menstrual cycle whose phase
was confirmed by ultrasound, hormonal and histological
criteria. A urinary LH test was also used to confirm ovulation,
and in post-ovulatory cycles, the sample was taken on day 6–8
post LH surge. All patients were receiving no exogenous hor-
monal treatment for at least 2 months prior to the procedure.
PCOS was defined using the Rotterdam criteria by the pres-
ence of two or more features of clinical and biochemical
hyperandrogenism, oligo-anovulation and/or polycystic
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ovaries (ultrasound) [20]. Related disorders such as tumours
producing androgens or patients with Cushing’s syndrome
were excluded.
Ovulatory PCOS patients had confirmed polycystic ovaries
on ultrasound and hyperandrogenism; ovulated spontaneous-
ly, with serum progesterone levels measured at LH+7 at least
30 nm/L; and were infertile despite regular ovulatory cycles in
the presence of patent tubes and normal sperm parameters.
Tubal patency was confirmed by either a HyCoSy scan or
laparoscopy and dye test. The patients in control and study
groups were matched for body mass index and smoking
habits.
Samples for histological evaluation and immunohisto-
chemical studies were taken with a sterile Pipelle endometrial
suction for sampling of the functional layer of the endometri-
um [21]. Blood samples were collected from patients at mid
proliferative (days 5 to 8) for routine fertility assessment of the
hormonal panel and at secretory phase (day 21, LH+7) for
progesterone, CD44, OPN and inflammatory cytokine levels.
Biopsies were taken at proliferative and secretory phases
timed with the blood sampling. Proliferative phase circulating
androgen levels were also assessed in the fertile and PCOS
patients. Patients with diagnosed coincident uterine pathology
that could modify the endometrial structure and function (as
hyperplasia, endometrial polyp or endometritis) were exclud-
ed from the study. Ethical approval was obtained from the
South Wales Local Research Ethics Committee (Wales 6 ref-
erence 05/WMW02/103 and 12/WA/0289); written consent
was obtained from all patients at the time of recruitment.
The study duration was 2 years from patient recruitment to
data collection and analysis.
Assessment of hormone levels in serum
Electrochemiluminescence immunoassays (ECLIA, Roche)
were used to measure the serum levels of testosterone
(Elecsys® Testosterone II assay), sex hormone–binding glob-
ulin (SHBG, Elecsys® SHBG assay), dehydroepiandroster-
one sulfate (DHEAS Elecsys® assay), progesterone
(Elecsys® Progesterone II), LH (Elecsys® LH) and FSH
(Elecsys® FSH) using an Elecsys 2010 immunoassay
analyser (Roche). Androstenedione was assayed using RIA
(Beckman Coulter). Samples with total testosterone levels
over 1.8 nmol/l were also analysed by LC-MS to confirm
values, as per NHS Wales policy; these values are reported
in Table 1.
Immunohistochemistry
Samples were fixed in 10% buffered formaldehyde for 24 h
and embedded in paraffin wax, and 3–4-μm-thick sections
prepared on positively charged slides for immunohistochem-
ical studies. The sections were de-waxed using a Roche
dewaxing solution. The tissue sections were incubated with
rabbit anti-human OPN polyclonal antibody (AB1870;
Millipore) and rabbit anti-CD44 monoclonal antibody (clone
EPR1013Y; Millipore), both diluted 1:100. Rabbit IgG was
used as negative control, and adjacent sections were cut and
stained in parallel using identical procedures. Renal cell can-
cer and tonsil positive control were used for OPN and CD44
respectively.
For antigen retrieval, the slides were incubated in CC1
buffer (Ventana Biotek Solutions, Tucson, AZ) for an hour
on heated plates at 100 °C on a Benchmark XT processor.
Primary antibody incubation was for 36 min at dilution
1:100 at 37 °C. Positive immunostainingwas detected through
interaction of avidin-biotin peroxidase (ABC) complex with
biotin conjugated secondary antibody using a Ventana I View
DAB detection kit (Ventana Biotek Solutions, Tucson, AZ)
and avidin-biotin blocker. The slides were subsequently coun-
terstained with haematoxylin, dehydrated, cleared and
mounted in DPX mountant to be examined under light mi-
croscopy. We used an immunohistochemical scoring system
(IHC) in which the observers perform a thorough examination
of all the immunohistochemical sections of the tissue slide
using a multi-headed microscope [22]. The endometrial epi-
thelium was assessed separately for the lumen and glands and
scored for intensity and distribution of staining. The intensity
of staining was scored from (0)—absent to (4)—strong. The
distribution of staining was assessed as follows: (0)—absent,
(1)—less than 30%, (2)—30 to 60%, (3)—more than 60% and
(4)—100% of the tissue surface stained (H-score). The ob-
servers were blinded to the patients’ diagnosis, demographics
and timing in the cycle of endometrial biopsy.
Cell culture
Regulation of OPN and CD44 was assessed in the Ishikawa
endometrial epithelial cell line (ECACC 99040201, STR au-
thentication, Public Health England, UK), a well-
differentiated human endometrial adenocarcinoma cell line,
expressing both ERα and PR A & B receptors, regulated in
a manner similar to that of normal endometrium [23].
Ishikawa cell lines at low passage number (passage number
≤ 22) were cultured at 37 °C with 5% CO2; at least 24 h prior
to experiments, the medium was changed to phenol red-free
media with 10% charcoal stripped FCS. Cells were stimulated
with pro-inflammatory cytokines TNF-α (25 ng/ml, 4 h)
(Miltenyi Biotec UK, Cat no. 130-094-014) and IFN-γ
(2 IU, 24 h) (Miltenyi Biotec UK, Cat no. 130-096-872) sep-
arately, or steroid hormones 17-β-oestradiol (E2; 10 nM, 48 h)
(Sigma-Aldrich, UK Cat-No E8875) and progesterone (P4;
1 μM, 48 h) (Sigma-Aldrich UK, Cat-No M1629) alone or
in combination as previously described [4, 24]. Following
stimulation, cell pellets were collected for mRNA and chro-
matin immunoprecipitation analysis. The presence of ERα,
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PRA and PRB receptors in Ishikawa cells was confirmed by
immunoblots (data not shown).
Immunoblot
Proteins were quantified (Bradford assay) and equal amounts
(20 μg) resolved by SDS-PAGE, transferred to PVDF mem-
branes and blocked overnight with 10% BSA, in 0.1% Tween-
20-TBS (TTBS). Membranes were subsequently incubated at
4 °C with rabbit anti-human ERα rabbit polyclonal antibody
(HC-20 Santa Cruz Biotechnology, USA) (diluted 1/500 in 5%
BSA-TTBS buffer) or anti-human PR A/B rabbit polyclonal
antibody (H-190 Santa Cruz Biotechnology, USA) (diluted 1/
1000 in 5% BSA-TTBS buffer). Blots were then incubated for
1 hwith IgG horseradish peroxidase secondary antibody diluted
1/2000 in 5% BSA-TTBS buffer. Between incubation steps,
membranes were washed several times with TTBS. Blots were
analysed for GAPDH levels (GAPDH rabbit polyclonal anti-
body (FL-335, Santa Cruz Biotechnology, USA)) to normalise
protein loading in each well. Immunoreactive bands were
visualised using a ChemiDoc System Bio-Rad Imager (Bio-
Rad) and quantified by Quantity One® Imaging software
(Bio-Rad), as described previously [3].
RNA isolation and qPCR
Endometrial biopsies were snap-frozen in liquid nitrogen im-
mediately following excision during the surgical procedure
and further stored in liquid nitrogen until subsequent analyses.
Total RNA was isolated from snap frozen biopsies and cell
line using a RNeasy mini Kit (Qiagen, UK). DNase-I-treated
RNA was reverse transcribed into cDNA (high-capacity
cDNA conversion; Applied Biosciences, UK) before
assessing CD44 and OPN expression using specific primer
pairs available on request (Beacon Design 2.0; Premier
Biosoft International, USA). qPCR amplification was per-
formed in triplicate in 96-well plates in a Bio-Rad IQ
iCycler. Serial dilutions of cDNA were used to plot a calibra-
tion curve, and gene expression was quantified by plotting
threshold cycle values. Expression levels were normalised to
values obtained for the reference gene Ribosomal Protein 60S
L 19 (RPL-19) [4].
Enzyme-linked immunosorbent assay
Serum samples (50 μl) were collected following centrifuga-
tion of blood samples at 1500 g for 10 min and stored at
−20 °C. Biopsy media was collected, centrifuged and stored
as described above prior to enzyme-linked immunosorbent
assay (ELISA) tests. The levels of CD44 (CD44 Human
ELISA Kit, Abcam, UK), OPN (Human OPN DuoSet
ELISA R&D Systems, UK), TNF-α (Human TNF-alpha
DuoSet ELISA, R&D Systems, UK) and IFN-γ (Human
IFN-gamma DuoSet ELISA, R&D Systems, UK) were mea-
sured in serum and in biopsy media by ELISA following the
manufacturer’s protocol. Samples were analysed in triplicate
and data obtained for in vitro experiments is representative of
four independent experiments.
Chromatin immunoprecipitation analysis
Ishikawa cell sample fixation, DNA shearing and chromatin
immunoprecipitation (ChIP) were performed following the
manufacturer’s instructions (Porvair Sciences, UK).
Table 1 Patients’ clinical data
Fertile Ovulatory PCOS Anovulatory
PCOS
Age 30 ± 4.6 29 ± 5.3(p = 0.7002) 29.1 ± 2.55(p = 0.562)
BMI (kg/m2) 26.78 ± 4.96 29.01 ± 5.02(p = 0.520) 32.33 ± 5.81(p = 0.076)
Progesterone day 21 (ng/ml) 31 ± 5.28 27.45 ± 11.5(p = 0.597) N/A
FSH (mUI/ml) 7.4 ± 3.017 5.67 ± 1.37(p = 0.135) 5.34 ± 2.57(p = 0.2041)
LH (mUI/ml) 4.90 ± 2.221 12.70 ± 4.27(p = 0.0004) 15.63 ± 4.94(p = 0.0008)
FSH/LH ratio 1.623 ± 0.57 0.48 ± 0.151(p = 0.0001) 0.363 ± 0.19(p = 0.0005)
Total T (nmol/l) 0.76 ± 0.472 1.72 ± 0.313(p = 0.1) 2.94 ± 0.108(p = 0.001)
Free T (pmol/l) 13.13 ± 6.12 18.5 ± 5.7(p = 0.08) 37.15 ± 10.6(p = 0.002)
Free androgen index 4.10 ± 0.81 5.6 ± 0.39(p = 0.05) 8.12 ± 1.16(p = 0.003)
SHBG (nmol/l) 42.60 ± 5.18 34.51 ± 2.97(p = 0.8) 27.92 ± 10.5(p = 0.05)
A (nmol/l) 3.43 ± 0.23 7.70 ± 1.6(p = 0.006) 8.72 ± 1.1(p = 0.0001)
DHEAS (μmol/l) 5.07 ± 0.76 7.26 ± 0.61(p = 0.03) 7.560. ± 0.32(p = 0.01)
Values are mean ± SDBMI body mass index, FSH follicle-stimulating hormone, LH luteinising hormone, T testosterone, A androstenedione, DHEAS
dehydroepiandrosterone
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Chromatin was quantified using a Nanodrop spectrophotom-
eter and visualised using agarose gel electrophoresis to ensure
correct distribution of fragment sizes prior to immunoprecip-
itation. Four hundred nanograms of each chromatin sample
was used per ChIP with 0.8 μg of the relevant antibody;
NF-κB anti-p65 (C-20, Santa Cruz Biotechnology, USA),
STAT1 (phospho Y701, ab30645, AbCam, UK), anti-ERα
(HC-20, Santa Cruz Biotechnology, USA) and non-specific
rabbit IgG (Rockland Inc., USA) antibodies were used.
Enriched fragments were reverse cross-linked, and protein
removed by protease digestion prior to qPCR. Specific primer
sets (available on request) for predicted NF-κB, STAT1 and
ERα binding sites in the OPN and CD44 promoters were used
to assess promoter occupancy by qPCR, whichwas performed
as described [25].
Statistical analysis
Data distributions were assessed for normality using the
Kolmogorov-Smirnov tests. Non-normally distributed data
were analysed with the Mann-Whitney U test applied post
hoc to determine statistical significance. For normally distrib-
uted data, an ANOVA test followed by a t test was used to
determine significant differences between groups. The test
statistic and corresponding P value were reported.
Correlations between CD44 and OPN immunostaining and
OPN and CD44 serum levels in each group were assessed
by the nonparametric Spearman test. Correlations between
TNF and IFN serum levels with OPN and CD44 levels in
media and serum were performed via Pearson correlation co-
efficient. All data analysis was performed using SPSS version
16.0 (SPSS, Chicago, IL).
Results
Clinical data
Ninety-three patients were enrolled in this study: 50 fertile
(20—proliferative phase, 30—secretory phase), 31 infertile
ovPCOS patients (10—ovulatory in proliferative phase,
21—secretory phase (ovPCOS)) and 12 infertile anovulatory
PCOS patients (anovPCOS in proliferative phase). Our previ-
ously published observations were used to determine the sam-
ple size of the study [4]. There was no statistically significant
difference in the mean age and body mass index (BMI) be-
tween the fertile and study groups (see Table 1).
The levels of FSH and progesterone were not significantly
different between ovulatory groups. LH was significantly
higher and an FSH:LH ratio of < 1 was detected in both
PCOS groups compared to controls. The PCOS groups
expressed significantly higher levels of androstenedione and
dehydroepiandtrosterone sulfate (DHEAS). Free testosterone
levels were not different from the controls in the ovPCOS
patients, but were significantly higher in the anovPCOS group
(see Table 1). The SHBG levels were only marginally higher
in the anovPCOS group.
Immunohistochemical evaluation of CD44 and OPN
expression in fertile and infertile endometrium
Expression of CD44 and OPN was assessed in both glandular
and luminal endometrial epithelium (see Figs. 1 and 2). In the
proliferative phase, endometrium of anovPCOS patients ex-
hibited significantly reduced glandular and luminal staining
levels of CD44 (p = 0.005, p = 0.001) and increased expres-
sion of OPN (p = 0.045, p = 0.045) compared to fertile endo-
metrium (see Fig. 1). No significant differences were observed
in CD44 or OPN expression between the proliferative endo-
metrium of ovPCOS and fertile patients (see Fig. 1).
Differences in OPN and CD44 expression were observed
in endometrial glands and lumen of fertile and infertile
ovPCOS endometrium during the secretory phase of the men-
strual cycle (see Fig. 2). A reduced expression of CD44 stain-
ing was observed in secretory phase endometrium of ovPCOS
(glands p = 0.027, lumen p = 0.022) compared to fertile pa-
tients (see Fig. 2a, b). Similarly, OPN glandular and luminal
staining was reduced in ovPCOS secretory endometrium
(glands p = 0.001, lumen p = 0.05) compared to fertile secre-
tory endometrium (see Fig. 2b, d).
Circulating levels of OPN, CD44 and inflammatory
cytokines TNF-α and IFN-γ are altered in infertile
patients
The expression of CD44 and OPN (serum and biopsy media),
together with levels of the pro-inflammatory cytokines TNF-α
and IFN-γ in serum samples during secretory phase from the
patient cohort used for IHC studies, was assessed by ELISA
(see Fig. 3). CD44 levels in serum and biopsy media were
significantly higher in ovPCOS patients (serum p = 0.012;
media p = 0.000) compared to fertiles indicating that the ele-
vated serum levels originate from endometrial tissue (see Fig.
3a). TNF-α and IFN-γ serum levels were significantly higher
in serum from ovPCOS patients (p = 0.0214, p = 0.0136)
compared to fertile patients (see Fig. 3a). Similarly, OPN
levels in serum and biopsy media were significantly higher
in ovPCOS (serum p = 0.001; media p = 0.000) patients com-
pared to fertile patients (see Fig. 3a).
Serum levels of CD44 and OPN were positively associated
with CD44 and OPN immunostaining levels in endometrium
of fertile patients during secretory phase (see Fig. 3b). In con-
trast, a significant negative association between serum and
tissue levels was observed in the ovPCOS group for both
OPN and CD44, with high serum and low tissue levels during
secretory phase (see Fig. 3b). A significant positive correlation
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was observed between CD44 and OPN serum levels and the
levels of these proteins detected in biopsy media for both
fertile and PCOS groups (see Fig. 3b, Fig. 1S and 2S).
Additionally, levels of CD44 measured in both serum and
media were found to be positively correlated to OPN levels
(see Fig. 3b, Fig. 3S). Both OPN and CD44 serum levels were
found to be positively correlated to circulating levels of
TNF-α and IFN-γ in both fertile and PCOS endometrium
(see Fig. 3b, Fig. 1S and 2S). These results support the con-
cept of CD44 and OPN as a functional complex present on
endometrial cells, the composition of which alters in PCOS
patients, possibly due to alterations in steroid hormones, their
receptors and pro-inflammatory cytokines. To understand the
mechanisms underlying these changes in CD44 and OPN,
in vitro assays were undertaken to determine whether they
were due to changes in gene regulation.
Steroid hormone regulation of CD44 and OPN in vitro
The expression of both OPN and CD44 is increased in the
secretory phase endometrium of fertile women, suggesting
they are regulated by oestrogen and progesterone hormones.
Ishikawa is an endometrial epithelial cell line commonly used
as an in vitro model for uterine receptivity studies, having
functional steroid hormone receptors [26] and expressing
CD44 and OPN [27]. Following treatment with E2 (p =
0.019), P4 (p = 0.001) or a combination of E2 + P4, a signifi-
cant increase in CD44 mRNA was observed in Ishikawa cells
(p = 0.001) (see Fig. 4a). A similar increase in OPN expres-
sion was observed after 48 h treatment (E2, p = 0.048; P4, p =
0.020; E2 + P4, p = 0.001) (see Fig. 4b) demonstrating that
both CD44 and OPN are positively regulated by E2 and P4.
The response observed following E2 treatment could be
due to a direct effect of activated ERα, which can exert its
function through targeting oestrogen response elements
(EREs), or indirectly via interactions with other transcription
factors including AP1 and SP1 [28]. Promoter analysis of
OPN and CD44 identified several adjacent ERE, AP1 and
SP1 binding sites in both genes; therefore, ERα occupancy
was analysed by ChIP (see Fig. 4c, d). A very high and
Fig. 1 Immunohistochemical assessment of CD44 and OPN expression
in proliferative endometrial epithelium. a CD44 staining levels in
endometrial biopsies showing reduced intensity of CD44 staining in
anovPCOS samples compared to fertiles. b OPN staining levels in
endometrial proliferative biopsies indicate a reduced intensity of OPN
staining in anovPCOS endometrium compared to fertile endometrium.
Immunohistochemistry staining scores for CD44 and OPN assessed in
glands and lumen are shown (panels c and d). Values are expressed as
median (circled x) and interquartile range (box and whisker). The
statistical analysis was performed using Kruskal-Wallis test followed by
a Mann-Whitney test. *p ≤ 0.05 and **p ≤ 0.001 are considered signifi-
cant. F, fertile patients (n = 20); anovulatory PCOS (anov PCOS, n = 12);
ovulatory PCOS (ovPCOS, n = 10)
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statistically significant increase in ERα occupancy was ob-
served at the EREs in both CD44 (ERE (−2071/−2067), p =
0.020) and OPN (ERE (−2695/−2691), p = 0.017) promoters
48 h following E2 stimulation, thereby confirming that OPN
and CD44 are directly regulated by ERα in human endome-
trial cells. Based on this observation and the increased levels
of ERα expression reported in endometrium of PCOS patients
[4, 29], it is likely that the increased levels of both OPN and
CD44 in endometrial biopsy media and serum are a direct
result of an increased occupancy of ERα on the promoter of
these genes.
Expression of CD44 and OPN is stimulated by
inflammatory cytokines, and results from increased
STAT1 and P65-NF-κB promoter occupancy
The effects of pro-inflammatory cytokines TNF-α and IFN-γ
on CD44 and OPN gene expression were also investigated
(see Fig. 5). A significant increase in CD44 (p = 0.001) and
OPN (p = 0.009) expression was observed following treat-
ment with TNF-α after 4 h (see Fig. 5a), and with IFN-γ after
24 h (see Fig. 5b), which also induced CD44 (p = 0.001) and
OPN (p = 0.045) expression.
Activation of NF-κB by TNF-α elicits an inflammatory
response, resulting in recruitment of NF-κB to cognate bind-
ing sites in many TNF-α regulated genes [30]. Analysis of
both CD44 and OPN promoters revealed putative NF-κB
binding sites, which we interrogated for occupancy by the
NF-κB subunit p65 (see Fig. 5c, d). Increased recruitment of
p65 to the CD44 (+956/+946, p = 0.03, Fig. 5c) and OPN
(−3168/−3120, p = 0.01; and 1871/−1860, p = 0.02, Fig. 5d)
regulatory sites was observed following 4 h TNF-α stimula-
tion. We also analysed whether OPN and CD44 regulation by
IFN-γ was mediated by the JAK-STAT pathway, as STAT1
binding sites were identified in the promoters of both genes
(see Fig. 5e, f). Significant increases in STAT1 recruitment to
STAT1B binding sites in the CD44 (−780/−682, p = 0.041;
Fig. 5e) and OPN (−1855/−1681, p = 0.0306; Fig. 5f) pro-
moters were observed following 24 h of IFN-γ stimulation.
These results demonstrate that CD44 and OPN regulation
by inflammatory cytokines TNF-α and IFN-γ is mediated by
the recruitment of NF-κB and STAT1 transcription factors to
the promoters of these genes, and is likely to occur in the
Fig. 2 Immunohistochemical assessment of expression of CD44 and
OPN in secretory endometrium. a The intensity of CD44 staining is
significantly reduced in ovulatory PCOS endometrium compared to that
of fertile endometrium. bOPN staining levels are significantly reduced in
ovulatory PCOS compared to those in controls. Immunohistochemistry
staining scores for CD44 and OPN assessed in glands and lumen are
shown (panels c and d). Values are expressed as median (circled x) and
interquartile range (box and whisker). The statistical analysis was
performed using Kruskal-Wallis test followed by a Mann-Whitney test.
*p ≤ 0.05 and **p ≤ 0.001 are considered significant. F, fertile patients
(n = 30); ovPCOS (n = 21)
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endometrial tissue of PCOS patients where the levels of these
two cytokines increase.
Discussion
OPN and CD44 are adhesion molecules involved in the
trophoblast-endometrial interaction, facilitating apposition of
the embryo [8, 31]. As well as being expressed in the endo-
metrium, both molecules are secreted by endometrial cells,
where they could bind to receptors on the blastocyst blocking
interaction with the endometrial surface.
The dysfunctional endometrium of the two PCOS groups is
characterised by a similar oestrogenic environment, overex-
pression of androgen receptor and either diminished
(ovPCOS) or lack of (anovPCOS) progesterone activity [32,
33]. We also revealed distinct expression patterns of OPN and
CD44 expression in ovulatory and anovulatory PCOS groups
during the proliferative phase. In anovPCOS endometrium,
which displays only proliferative features, CD44 levels were
lower, whereas OPN levels were higher, compared to those of
the fertiles. The high levels of OPN in anovPCOS patients
could be associated with the levels of oestrogen and androgen,
characterising this group of patients as OPN expression is
Fig. 3 Expression levels of
CD44, OPN, TNF-α and IFN-γ
in serum and media samples from
fertile (n = 30) and ovPCOS (n =
21) patients measured by ELISA.
a Expression levels of CD44 (se-
rum and media), OPN (serum and
media), serum TNF and serum
IFN-γ are significantly higher in
ovPCOS patients compared to
those in fertile patients during the
secretory phase. Values are
expressed as log (average) ± SD.
Statistical analysis of the data was
performed using a Student t test.
*p ≤ 0.05 and **p ≤ 0.01 are con-
sidered significant. b Association
between expression levels was
measured using the Spearman rho
coefficients (r) for comparisons
between IHC scores and serum
levels (ELISA), whereas all other
associations were analysed using
the Pearson correlation test. *p ≤
0.05 and **p ≤ 0.001 are consid-
ered significant. F, fertile patients
(n = 30); ovPCOS (n = 21)
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reduced in endometrium cells exposed to the AR inhibitor
flutamide and endometrial PCOS cells exhibit an increased
expression of ERα nuclear receptor co-activators that may
enhance the oestrogen activity in these cells [34, 35]. The
decreased levels of CD44 in anovPCOS during proliferative
phase mirror the levels observed for ovPCOS in secretory
phase promoting the concept of dysfunctional endometrium
in PCOS patients, regardless of progesterone action.
Here, decreased levels of OPN and CD44 were observed in
the secretory endometrium of ovPCOS patients compared to
fertiles, whereas levels of CD44, OPN and pro-inflammatory
cytokines were increased in serum, as well as in the media
used to collect endometrial biopsies suggesting that circulat-
ing CD44 and OPN are of endometrial origin in these infertile
patients. In fertiles, serum and endometrial levels of CD44 and
OPN showed a positive association, which was also true be-
tween CD44 and OPN levels supporting the notion that these
proteins form a functional complex on a receptive endometrial
cell surface. The increased levels of circulating CD44 and
OPN in PCOS serum samples correlate positively with the
levels measured in the media in which PCOS biopsies were
collected and inversely with endometrial expression levels of
these two proteins. These results suggest that the presence of
OPN at the endometrial surface is dependent on the expression
of its receptor CD44 at the endometrial epithelial cell mem-
brane. Interestingly, these findings agree with studies that re-
veal that interaction between CD44 and OPN represents a
crucial ligand-receptor pair that facilitates systemic insulin
resistance [36, 37].
Both OPN and CD44 were directly regulated by ERα oc-
cupancy of the cognate ERE promoter site in both genes. In
PCOS patients, this nuclear receptor activation is probably
due to the local hyperoestrogenic uterine environment in in-
fertile ovulatory PCOS patients and the unopposed oestrogen
environment in anovulatory PCOS endometria where
oestrogen levels are modulated by hydroxysteroid dehydroge-
nase (HSD) enzymes [38]. In support of this notion, we have
previously described that endometrial levels of 17β HSD-1
are significantly higher in PCOS endometrium compared to
those in fertiles [4]. In PCOS patients, inflammatory cytokines
are present in the pelvic peritoneal fluid, creating a pro-
inflammatory environment in the uterus, which also responds
to elevated levels of TNF-α and IFN-γ in the blood of these
patients. The elevated expression levels of TNF-α may also
Fig. 4 Regulation of OPN and
CD44 endometrial expression by
oestrogen and progesterone
hormones. a, b Transcript levels
of CD44 and OPN in Ishikawa
cells treated for 48 h with
hormones E2 (10 nM) and P4
(1 μM) were analysed by qPCR.
Values, normalised to RPL19, are
expressed as the average ± SD.
Results are representative of three
biological repeats. Statistical
analysis of the data was per-
formed using a Student t test.
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤
0.001 are considered significant.
c, d Quantitative analysis of ERα
occupancy of CD44 and OPN
promoter was assessed after E2
(10 nM) stimulation of Ishikawa
cells (ERα +ve) by chromatin
immunoprecipitation. Results are
representative of three biological
repeats. Values are expressed as
the average ± SD. Statistical anal-
ysis of the data was performed
using a Student t test. *p ≤ 0.05,
**p ≤ 0.01 and ***p ≤ 0.001 are
considered significant
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facilitate the increase of testosterone levels in PCOS patients
[39]. Based on our observations, it appears that these cyto-
kines could directly regulate CD44 and OPN expression
through both STAT1 and NF-κB pathways in the endometri-
um of PCOSwomen. Given the direct regulation of CD44 and
OPN expression by ERα, NF-κB and STAT1, therapeutic
interventions that directly target these transcription factors
could be beneficial in restoring correct OPN and CD44
expression.
The increased oestrogenic environment, coupled with con-
comitant increased levels of pro-inflammatory cytokines, ap-
pears to create a microenvironment conducive to abnormal
endometrial expression of CD44 and OPN (see Fig. 6). This
would lead to the establishment of two processes that could
contribute to the associated infertility. First, elevated levels of
OPN and CD44 circulating molecules, possibly due to
increased proteolytic cleavage of CD44, could block these L-
selectin receptors on the surface of blastocysts, preventing
their attachment to the endometrial surface. This effect would
be exacerbated by the abnormal ratio of OPN and CD44 pro-
teins resulting in the formation of non-functional adhesion
complexes (anovPCOS) or a simple lack of adhesion complex
density on the endometrial epithelium of ovPCOS patients.
Considering the levels of cytokines, CD44 and OPN at
tissue and blood levels, it is important to take into consider-
ation in vivo, the dialogue between these markers, the
hyperoestrogenic environment and the other non-ovulation-
related factors affecting fertilisation and implantation.
Notably, the parallel between the tissue and blood values,
reported in this study and timed in the menstrual cycle, makes
blood biomarkers an attractive less invasive option to imple-
ment as part of fertility investigations. It is also important to
Fig. 5 Regulation of OPN and
CD44 endometrial expression by
TNF-α and IFN-γ. a, b
Transcript levels of OPN and
CD44were analysed by qPCR for
Ishikawa cells after treatment
with pro-inflammatory cytokines
TNF-α (25 ng/ml) or IFN-γ
(2 IU). Values, normalised to
RPL19, are expressed as the av-
erage ± SD. Results are represen-
tative of three biological repeats.
Statistical analysis of the data was
performed using a Student t test.
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤
0.001 are considered significant.
c, d Quantitative analysis of
CD44 and OPN promoters was
conducted using qPCR after
TNF-α (25 ng/ml) treatment to
measure NF-κB (p65) occupancy
in Ishikawa cells. A similar anal-
ysis was performed for the CD44
and OPN promoters to measure
the occupancy of STAT1 tran-
scription factor after treatment
with IFN-γ1b (2 IU) (e, f). Values
are expressed as the average ±
SD. Results are representative of
three biological repeats. Statistical
analysis of the data was per-
formed using a Student t test and
significance differences described
as *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001
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acknowledge the differences in fertility profiles in women
with ovulatory and anovulatory PCOS. Overall, the ovulation
and fertilisation processes are just as important as the implan-
tation process, which is dependent on a regular menstrual
cycle. Abnormal function at this level can explain the higher
incidence of silent and recurrent miscarriages in PCOS wom-
en with ovulatory and non-ovulatory cycles.
In conclusion, our findings reveal a novel molecular mech-
anism which highlights the crosstalk between the CD44-OPN
adhesion complex and STAT1 and NF-κB pathways modu-
lating endometrial receptivity. Abnormal CD44-OPN adhe-
sion complex formation could alter trophoblast-endometrial
interactions, thereby hindering interactions between the endo-
metrial epithelium and the outer trophectoderm cells of the
blastocyst. Therefore, this abnormal circulation of CD44 and
OPN can be exploited as a possible biomarker for early diag-
nosis of infertility and further enhance current clinical practice
in the diagnosis of endometrium receptivity status of patients.
The identification of treatments to modify the interaction be-
tween the ligand/receptor pair of CD44 and OPN may poten-
tially contribute to the improved diagnostic status of infertile
PCOS patients.
Limitations
Limitations include the fact that recruitment of patients for
endometrial studies is known to be challenging, and for this
reason, the number of endometrial tissue samples remains
limited specifically for ovPCOS patients in proliferative phase
resulting in the wide interquartile range described in Fig. 1.
We are also aware of the difficulty of comparing in vitro re-
sults with in vivo findings. Hence, even though we tested
steroid hormone and pro-inflammatory cytokine effects in an
in vitro environment, we could not consider, in our in vitro
model, the roles of systemic hyperoestrogenism or chronic
inflammation, both common features in PCOS. Another lim-
itation of the study is that the homeostasis model assessment
of insulin resistance (HOMA-IR) [40] is not routinely inves-
tigated in clinical practice. Hence, the positive correlation of
CD44 and OPNwith the altered HOMAwas not assessed, but
we can confirm that none of the patients recruited in this study
had known type 2 diabetes.
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